-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
PD-1 blockade is very effective for classic Hodgkin’s lymphomas (cHLs), which is manifested by frequent increase in the copy number of CD274 (PD-L1) and PDC1LG2 (PD-L2) on chromosome 9p24.
Lymphoma immunity
The study included 56 patients who participated in the CheckMate 205 phase II clinical trial (NCT02181738) and obtained peripheral immune characteristics that are responsive to PD-1 blockade.
Fig.
diagnosis
In summary, these findings emphasize the role of the recently expanded, clonally diverse CD4+ T cells and innate effectors in the efficacy of PD-1 blockade in the treatment of cHL.
Original source:
Fathima Zumla Cader, et al.
ncbi.
nlm.
nih.
gov/32778827/" target="_blank" rel="noopener">A peripheral immune signature of responsiveness to PD -1 blockade in patients with classical Hodgkin lymphoma
in this message